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The aging process correlates with a progressive failure in the normal cellular and organ functioning; these
alterations are aggravated in Alzheimer’s disease (AD). In both aging and AD there is a general decrease in the
capacity of the body to eliminate toxic compounds and, simultaneously, to supply the brain with relevant growth
and nutritional factors. The barriers of the brain are targets of this age related dysfunction; both the endothelial
cells of the blood–brain barrier and the choroid plexus epithelial cells of the blood-cerebrospinal fluid barrier
decrease their secretory capacity towards the brain and their ability to remove toxic compounds from the brain.
Additionally, during normal aging and in AD, the permeability of the brain barriers increase. As such, a greater
contact of the brain parenchyma with the blood content alters the highly controlled neural environment, which
impacts on neural function. Of interest, the brain barriers are more than mere obstacles to the passage of
molecules and cells, and therefore active players in brain homeostasis, which is still to be further recognized and
investigated in the context of health and disease. Herein, we provide a review on how the brain barriers change
during aging and in AD and how these processes impact on brain function.
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Increases in lifespan over the last decades have, unfor-
tunately, not been matched by improvements in the
mental health span. While some individuals age
“healthily”, others present accelerated cognitive decline.
Persons over the age of 65 have high risk of developing
Alzheimer’s disease (AD), the most common type of
dementia. AD affects approximately 28 million people
worldwide and it is 1 in 85 persons (or 106 million
people) will suffer from AD [1]. The need to counter
these disorders, based on improved mechanistic under-
standing of their etiopathogenesis cannot, therefore, be
underestimated.
The main pathological features of AD are the extra-
cellular deposition of amyloid β peptide (Aβ) into
plaques and the formation of intracellular tangles com-
posed of hyperphosphorylated Tau protein [2]. Various
lifetime parameters, such as chronic stress and exposure to* Correspondence: japalha@ecsaude.uminho.pt
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reproduction in any medium, provided the orinflammatory stimuli have been suggested to predispose in-
dividuals to AD, and several molecular pathways have been
implied in the disease [3,4]. In this review we will focus on
the involvement of the brain barriers in aging and in AD.
This topic is still poorly investigated, especially in normal
aging, but is of relevance given the ability of the brain bar-
riers to maintain and regulate the environment for the
normal neuronal activity. Thus, alterations in the bar-
riers’ morphology, secretome and functioning can com-
promise central nervous system (CNS) homeostasis. A key
message from this review is that the brain barriers are not
mere obstacles to the passage of molecules, cells and drugs
into and out of the brain (which by itself is of relevance for
clearance of Aβ peptides); in fact, they actively contribute
to brain homeostasis and display specific responses to
events that occur in the periphery and in the brain
parenchyma, which should be taken into consideration
in understanding diseases of the CNS.The barriers of the brain
CNS homeostasis is essential for the proper functioning
of brain cells. The blood–brain barriers participate in CNSl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to the constant oscillations in the concentration of blood
constituents and by transporting nutrients and products
from brain metabolism in and out of the brain, respectively.
Two main barriers separate the CNS from the periphery:
the blood–brain barrier (BBB) and the blood-cerebrospinal
fluid barrier (BCSFB) [5]. While the BBB has been well
recognized for long; the BCSFB is more rarely mentioned,
which is to regret when considering its functions, which
include producing most of the cerebrospinal fluid (CSF).
The existence of the brain barriers is in part respon-
sible for the initial concept that the brain is an immune-
privileged site, with restricted passage of immune cells into
the brain. In fact, even though in a healthy person under
physiological conditions, immune cell migration across the
brain barriers is low, some migration exists and is required
for the immune surveillance of the CNS [6,7]. However,
during normal aging and in several diseases of the CNS,
such as multiple sclerosis and AD, changes in blood com-
position, brain inflammation and the facilitated entrance of
immune cells through the brain barriers can potentially
cause neuronal damage and cognitive dysfunction [8-10].
While the brain barriers protect the neural milieu from
drastic concentration changes in blood molecules such
as nutrients and ions, the brain still senses changes in
specific blood constituents to rapidly respond accordingly.
Specific brain regions, called circumventricular organs (area
postrema, median eminence, pineal gland, posterior pi-
tuitary, subfornical organ, subcomissural organ, and the
vascular organ of the lamina terminalis) are deprived of
BBB and, therefore, continuously monitor the blood
composition. In these areas the protection of the brain
parenchyma is ensured by tanycytes [11].
The blood–brain barrier
The BBB is formed by tight junctions present between the
endothelial cells of the capillaries that perfuse the brain
parenchyma. On a larger organizational level, the basal
lamina, astrocytic end-feets and pericytes that surround the
central BBB core, altogether, constitute what is designated
as the neurovascular unit (Figure 1A). The total length of
capillaries in the human brain is of approximately 600 Km,
with a capillary surface area of about 20 m2 [12]. In fact,
almost every neuron is perfused by its own capillary,
which highlights the dimension of this interface between
the blood and the brain parenchyma.
Except for small lipophilic molecules such as O2 and
CO2, which diffuse freely across endothelial cells along
their concentration gradient, access through the brain
barriers of blood-born molecules requires the presence of
specific transporter or receptor systems. Nutrients like glu-
cose and amino acids enter the brain through specific
transporters, while molecules such as insulin, leptin
and transferrin are transported by receptor-mediatedendocytosis [13,14] (Figure 1B). Conversely, similar mech-
anisms constitute a way out of the brain for molecules
produced by brain cells metabolism; both through passive
diffusion and via transporters and receptors located on the
“brain side” of the endothelial cell, such as for glutamine
and Aβ peptides [15].
Blood-cerebrospinal fluid barrier
The BCSFB is formed by the choroid plexus (CP) epithelial
cells. The CP is phylogenetically and ontogenetically con-
served. The CP develops early during embryogenesis and
already constitutes a functional barrier within the first
weeks of gestation [16,17]. Before this barrier is formed, the
neuroependymal cells lining the ventricular wall are
connected by strap junctions, halting the passage of large
molecules into the brain parenchyma [17]. The CP is posi-
tioned within the ventricles of the brain: one in each lateral,
one in the third and one in the fourth. Grossly, the CP is a
lobulated structure formed by a unique and continuous line
of epithelial cells originating from the ependymal wall of
the ventricles, which floats in the CSF space. These epithe-
lial cells are bound to each other by tight junctions and rest
on a basal lamina and on a central core formed by connect-
ive and highly vascularized tissue (Figure 2A). The apical
side of the epithelial cells faces the CSF and contains nu-
merous villosities, while the basolateral side faces the blood,
lying in the stroma in contact with several capillaries. Of
notice, the capillaries that irrigate the CP are fenestrated, i.
e. at the CP there is no BBB. In addition to the fenestrated
capillaries, dendritic cells, fibroblasts and macrophages
populate the central core of the CP stroma. Although the
passage of molecules and cells is possible in the
vascularized stroma, these do not reach the CSF through
paracellular transport due to the tight junctions between
CP epithelial cells. Ultrastructurally, the epithelial cell con-
tains numerous mitochondria, Golgi apparatus, smooth
endoplasmic reticulum and lysosome-like vesicles, which
demonstrates that it is a structure with great synthetic cap-
acity. The main CP function is the production of CSF [18]
(Figure 2B). The CSF is a clear, slightly viscous liquid with
few cells and a protein concentration about 10 times lower
than that of the blood [19]. An adult human contains ap-
proximately 150 ml of CSF filling the ventricles, the sub-
arachnoid space and the spinal cord, and these are renewed
3–4 times daily, testifying to the great secretory capacity of
the CP epithelium. Drainage of CSF occurs at the arachnoid
villus in the venous sinus.
By influencing the CSF composition, which ultimately
impacts on the brain parenchyma, the CP may interfere
with brain homeostasis in health and in disease.
The brain barriers in aging and in Alzheimer’s disease
The brain has two fluid environments: the brain interstitial
fluid, which surrounds the neurons and glia, and the CSF.
Figure 1 Neurovascular unit composition, function and alterations in aging and in AD. (A) The BBB is formed by the tight junctions that
connect the endothelial cells of the brain capillaries. These are surrounded by a basal lamina, pericytes and by astrocytes end-feets, and may as
well interact directly or indirectly with neurons. (B) The endothelial cells of the BBB contain in the luminal and abluminal sides transporters and
receptors. (C) Several alterations are observed at the endothelial cells of the BBB during aging and in AD.
Marques et al. Molecular Neurodegeneration 2013, 8:38 Page 3 of 9
http://www.molecularneurodegeneration.com/content/8/1/38Interaction between the periphery and the brain paren-
chyma has, therefore, to occur through the CSF and/or
through the neurovascular unit. Both the BBB and the
BCSFB contain transporters and receptors in the basolateral
and apical sides, and therefore are able to transport mole-
cules into and out of the brain, and to convey receptor-
mediated signals, similarly in both directions. What is
striking and still far from being fully understood is how
the brain barriers themselves respond to stimuli, as re-
cently shown by alterations in the CP transcriptome in
response to peripheral inflammatory stimuli [20,21],
and in the BBB transcriptome similarly in response toFigure 2 BCSFB composition, function and alterations in aging and A
in the ependymal cells that line the brain ventricles, forming a closed struc
transporters and receptors in both the basolateral and apical sides. (C) Sev
aging and in AD.systemic inflammation and to infection [22]. This brings
the brain barriers to a novel level of complexity since
changes in their functions may be critical to control/
prevent/treat diseases of the CNS.
During aging and in AD several alterations are observed
in the cellular elements of the neurovascular unit and in
the CP epithelia. At the neurovascular unit these consist of
focal necrosis of the cerebral endothelium, accumulation of
extracellular matrix components in the vascular basement
membrane, decreased endothelial mitochondrial density,
increased pinocytotic vesicles, loosening of tight junctions,
changes in the astrocytic endfeet and stiffening of the vesselD. (A) The CP is formed by a monolayer of epithelial cells originating
ture – the stroma. (B) CP produces CSF. CP epithelial cells contain
eral alterations are observed at the epithelial cells of the BCSFBB during
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perfusion) [23,24] (Figure 1C). Furthermore, normal aging
and AD are accompanied by a significant decrease in
microvessel density [25]. Sensitive neuroimaging methods
confirm aging-related regression in global and regional
measures of cerebral blood flow (∼4 mL/min/year), cerebral
metabolic rate for oxygen, glucose oxidation and cerebral
blood volume [26]. Interestingly, deficiency of perycites
(one of the elements of the neurovascular unit) has been
shown to compromise the integrity of the BBB and lead to
brain hypoperfusion resulting in secondary neurodegenera-
tive changes [27,28]. Similarly, the aged human CP exhibits
cellular atrophy, decreased CSF production, enzymatic and
metabolic activities, and impaired capacity for the efflux
and clearance of molecules [29-31] (Figure 2C).
The aged CP epithelial cell cytoplasm becomes rich
with Biondi ring tangles and lipofuscin deposits, which is
also observed in the CP of AD patients [32]. Additionally,
irregular and flattened basement membrane thickening
is also observed in the aged CP [29]. The stroma also
thickens and contains collagen fibers, hyaline bodies
and calcifications while the infiltrating arteries become
thicker and fragmented [29,30].
With respect to CSF dynamics, studies in humans and
in rodents [33,34] revealed decreased CSF production and
turnover in the aged brain. Interestingly, Aβ1-40 and
Aβ1-42 concentrations in the cortex and hippocampus
were also reported to increase from 3 to 30 months
[33], suggesting that the decrease in the CSF turnover
and the continuous Aβ brain accumulation are contribut-
ing to AD pathology [33,35]. A general feature of aging
that is accelerated in AD is an increase in the barriers
permeability, as revealed by higher protein leakage from
the blood into the CSF [31,36] (Figures 1 and 2C).
Recognition that the barriers’ properties and metabolism
change with age and are subject of alterations in response
to specific stimuli, make them physiologically interesting
in the context of brain function in “healthy“ aging and in
disease. We will next briefly specify two examples in
which changes at the brain barriers are of relevance for
aging and AD: i) the transport of the Aβ peptide since
accumulation of Aβ may result from increased Aβ pro-
duction or decreased Aβ efflux out of the brain [30,37],
and ii) the response of the barriers to inflammation, not
only given the inflammatory component that is present in
the AD brain, but also because peripheral inflammatory
stimuli have been shown to alter the barriers homeostasis
with respect to processes such as iron regulation, which
impacts in AD [38].
Aβ transport through the brain barriers in
Alzheimer’s disease
One of the pathological hallmarks of AD is the increased
production and accumulation of Aβ peptides in the brain.These peptides result from the sequential cleavage of the
transmembrane amyloid precursor protein (APP). Due to
an unidentified combination of events, Aβ monomers can
aggregate into oligomers, and then deposit in the form of
extracellular amyloid plaques in different regions of the
brain [39,40]. The accumulation of these peptides can
result both from the increased production but also from a
decrease in their excretion through the brain barriers [41].
Thus, excretion of Aβ out of the brain represents a rele-
vant mechanism of the disease and a therapeutic target.
Various transporter systems seem to operate at the brain
barriers. Although not specific for Aβ, these are involved in
receptor-mediated flux of Aβ: the low-density lipoprotein
receptor-related protein (LRP), the receptor for advanced
glycation end products (RAGE), the receptor glycopro-
tein330 (gp330)/megalin (LRP-2)-mediated transcytosis,
and the ATP-binding cassette, sub-family B (MDR/TAP),
member 1 (ABCB1 also known as P-glycoprotein or Pgp)
[15,23,42]. While LRPs and ABCB1 mediate the efflux of
Aβ from the brain to the periphery, RAGE has been impli-
cated in the Aβ influx to the brain from the periphery
[15,37]. The expression of both types of receptors at the
BBB is altered with age; the expression of the Aβ efflux
transporters is decreased while that of the Aβ influx trans-
porter is increased, adding to the amyloid burden in the
brain [15,43]. LRP-1 and ABCB1 staining of microvessels
revealed that there is an age-dependent loss of capillary
LRP-1 and ABCB1 and that the expression of LRP-1 cor-
related negatively with the expression of RAGE [43],
which seems to progressively contribute to Aβ accumula-
tion in aging (Figure 1C). In addition, single-nucleotide
polymorphisms in the ABCB1 gene found in AD patients
may be related to changes in ABCB1 function at the BBB.
As such, genetic variations in ABCB1 might contribute to
the progression of Aβ deposition in the brain [44,45].
As for the BCSFB, LRP-2 has been found to decrease
with age, which supports decreased clearance of Aβ [46].
Of interest, a recent study in old rats confirmed reduced
LRP-2 but showed an increase in the transcription of the
Aβ efflux transporters LRP-1 and ABCB1 and no changes
in RAGE expression [47] (Figure 2C). These observations
in efflux transport regulation are on the opposite direction
from those reported in the BBB. Therefore, it is the overall
balance of these transporters at both barriers that finally
determines the net flow of Aβ in aging and in AD.
Still related with Aβ removal from the brain, three
CSF circulating proteins deserve specific consideration:
transthyretin (TTR), clusterin (or apolipoprotein J), and
insulin-like growth factor 1 (IGF1).
TTR [48] is a 55-kDa tetrameric protein synthesized
mainly by the liver and by the CP [49,50] from where it
is secreted into the blood and the CSF, respectively. TTR
synthesis represents 20% of the total protein synthesized
by the CP. TTR is a plasma and CSF carrier for thyroxine
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protein (RBP)] [51]. Although TTR has been initially
proposed to be essential to mediate thyroid hormone
and retinol transfer into the tissues, particularly into the
brain and across the BCSFB, studies with a TTR-null
mouse strain showed that TTR is neither necessary for thy-
roid hormones entry into and distribution within the brain
and other tissues, nor for the maintenance of a euthyroid
status [51,52] or for retinol delivery to the tissues [53].
However, both TTR ligands may, themselves, be of rele-
vance in aging and in AD, as exemplified by reports on
the ability of retinoids to diminish amyloid aggregation
and to improve cognition [54,55]. As for Aβ, TTR is able
to bind it both in vitro and in vivo [56] and, by sequester-
ing Aβ in the CSF, TTR has been suggested to prevent
amyloid plaques formation [57-59] and to mediate CP
clearance of Aβ. Studies in which TTR-null mice were
crossed with animal models of AD have led to contradict-
ory results on whether, in vivo, the absence of TTR ame-
liorates [60,61] or accelerates [62] the AD-like phenotype.
Interestingly, the absence of TTR, per se, has been shown
to accelerate the cognitive decline associated with aging
[63]. Studies in humans found decreased TTR levels in
the CSF of AD patients [64], which may result from the
decreased CP secretory activity described to occur with
aging [26]. Furthermore, TTR is also decreased in the
blood of individuals with mild cognitive impairment and
with AD [65]. These observations suggested that mutated
forms of TTR, with decreased affinity to Aβ, could be
associated with AD; however, no mutations in TTR were
found associated with the disease [66].
Clusterin is another blood and CSF carrier of soluble
Aβ [67] synthesized by the CP [68]. Genome-wide associ-
ation studies found clusterin linked to AD [69] and some
studies suggested that its circulating increased levels could
be part of a panel of markers of the disease [70]; the latter
is however controversial as other studies showed no asso-
ciation [71]. Clusterin levels in AD brain are higher than
those in control subjects: in a recent immunohistochemis-
try characterization, a unique and specific association
between clusterin and Aβ1-40 (but not with Aβ1-42)
plaques was observed in the cerebral cortex and in the
cerebrovasculature of AD subjects [72]. As such, clusterin-
bound Aβ1-40 seems prone to deposit in the AD brain.
On the contrary, binding to clusterin may facilitate its
transport across the BBB and the BCSFB through LRP-2
[68,73]. Therefore, the factors that determine whether
clusterin is protective or detrimental in AD remain to be
clarified.
IGF-1 is among the proteins synthesized and secreted
by the CP described as neuroprotective in the context
of AD, given its ability to participate in the clearance of
Aβ out of the brain. In accordance, treatment of mice
over-expressing mutant APP/ presenilin-1 (APP/PS1) withIGF-1 reduced brain Aβ burden [74], an effect suggested
to be mediated by interaction with the LRP2 Aβ clearance
pathway [75], but also related to an increase in the con-
centration of other Aβ carrier proteins (including TTR
and clusterin). As a promiscuous receptor, LRP-2 is also
able to transcytose insulin and IGF-1 [76,77]. Therefore,
IGF-1 directly produced by the CP or originating from the
blood may enhance the transport of Aβ out of the brain
[74,77]. Since levels of APP are not modified after IGF-1
therapy, and in vitro data indicate that IGF-1 increases the
transport of Aβ/carrier protein complexes through the
BCSFB, it seems that IGF-1 favors elimination of Aβ from
the brain, supporting a therapeutic use of this growth
factor in AD [77].
Blood–brain barriers and inflammation: impact on aging
and Alzheimer’s disease
In a healthy person, immune cell migration through the
brain barriers is low. However, as it happens in neuro-
inflammatory diseases, an increased number of immune
cells reach the CNS during aging and in AD [78,79]. Both
aging and AD are associated with altered immune re-
sponse, namely with an increase in the production of in-
flammatory mediators.
Two levels of discussion seem to be relevant with respect
to AD: the inflammatory response that is present in the
vicinity of the amyloid plaques and the one that occurs at
the level of the brain barriers, especially at the BBB, since
considerable evidence implicates vascular inflammation in
aging and in AD. Although cerebral vascular endothelial
cell dysfunction and leukocyte transmigration across the
BBB are described as early events in the development of
AD, it is difficult to delineate whether they represent a
cause or a consequence of the disease; but they certainly
contribute for the perpetuation of the diseased brain [9,10].
In what concerns AD and inflammation, it is known that
Aβ enhances microglia and macrophage activation and in-
duces secretion of proinflammatory cytokines and
chemokines [80,81]. Recent neuropathological studies
showed a close relationship between fibrillar Aβ deposits,
inflammation and neurodegeneration in relatively early
stages of AD [82]. With respect to blood vessels and
inflammation in AD, Aβ appears directly involved in the
degeneration of both the larger perforating arterial vessels
and in the cerebral capillaries that constitute the BBB. The
cerebrovascular pathology in AD also encompasses macro-
and micro-infarctions, hemorrhages, lacunas, and ischemic
white-matter changes [83,84]. Additionally, immunofluor-
escent analysis of the cerebrovasculature in AD mouse
models demonstrates significant increases in thrombin,
hypoxia-inducible factor 1α, interleukin-6 (IL-6), monocyte
chemoattractant protein-1 (MCP-1), matrix metallopro-
teinases and reactive oxygen species [85]. Additionally,
isolated brain microvessels obtained from AD patients
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kines and chemokines including interleukin-1 beta, IL-6,
interleukin-8, tumor necrosis factor -, transforming
growth factor-beta and MCP-1, when compared to
age-matched non-AD controls [86-88]. Interestingly,
the protective effect of serum IGF-1 in the regulation
of brain Aβ levels is antagonized by tumor necrosis
factor-, a pro-inflammatory cytokine putatively involved in
dementia and aging [74].
Peripheral inflammatory conditions may also trigger
the barriers and modulate their response in aging and in
CNS diseases. Of interest, whether sustained or repeated
exposure to inflammation increases susceptibility to diseases
of the CNS is still to be determined. Accordingly, an
increasing body of evidence supports the relevance of
brain barriers-specific responses to inflammation. While
single acute exposure to peripheral lipopolysaccharide
(LPS) results in a rapid and transient response of the CP
transcriptome [20], continuation of the same stimuli in a
repeated chronic mode results in a more attenuated CP
response [21]. Similarly, the endothelial cells of the BBB
have both constitutive and induced expression of receptors
for different proinflammatory ligands that have the ability
to stimulate various signaling pathways that are equally
responding to peripheral LPS in the CP [21,22]. Of notice,
when LPS is administered to the Tg2576 APP mouse
model of AD, an increased level of brain IL-6 is observed.
Moreover, the permeability of the BBB is increased
suggesting vulnerability of the BBB to inflammation in
this animal model of AD [89]. Interestingly, however, is
the finding that intracranial administration of LPS to
promote neuroinflammation results in a reduction in
Aβ burden due to microglial activation [90].
When analyzing the barriers response to LPS/peripheral
inflammation, one of the genes whose expression was
found altered in the CP and in the BBB is that encoding
for lipocalin 2 (LCN2) [91], an acute phase response
protein that binds iron-loaded bacteria siderophores
[92,93]. This initial finding led to a detailed analysis of
iron homeostasis in the CP, which revealed that the CP
is able to regulate iron homeostasis in the brain, a novel
concept of regional iron homeostasis [38]. Iron is a medi-
ator of oxidative stress and accumulates in the AD brain.
Of notice, the APP gene has an iron-response element in
its 5′untranslated region [94] and was shown to have
iron-export ferroxidase activity [95]. Also recently, iron
was shown to induce Aβ aggregation since the presence of
Fe3+ during the Aβ aggregation process blocks the fusion
of fibrils into the less toxic amyloid deposits and favors
the stabilization of more toxic intermediate forms [96].
Iron access to the brain occurs by transferrin-mediated
endocytosis both at the BBB and at the BCSFB. It is
therefore likely that changes in brain barrier homeostasis,
either with respect to transport system or through alteredtranscriptome may predispose the brain to increased
iron-mediated oxidative stress. Of interest, decreased levels
of CSF LCN2 were found in individuals with mild cognitive
impairment [97,98], and mice lacking LCN2 presented
cognitive impairment [99]. Furthermore LCN2 was shown
to enhance the toxicity of glutamate and Aβ [98] and to
regulate neuronal morphology and excitability in the hippo-
campus and in the amygdala upon acute stress [100,101],
which could have impact on the neuronal dysfunction that
is observed during aging and in response to AD.
Conclusions
Here we highlighted that the communication between the
periphery and the brain, through the brain barriers, is
compromised in aging and in AD. Not only alterations in
the brain barrier transport mechanisms may influence clear-
ance of Aβ out of the brain, but also homeostatic mecha-
nisms present at the brain barriers, such as their secretome
and receptor-mediated signaling, can participate in the
neuroinflammation observed in AD. While the literature is
revealing that the barriers are active participants in brain
homeostasis, additional studies are still required to fully
understand on how the barriers function is altered in aging
and contribute to neurodegenerative diseases such as AD.
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